Jennifer M Giltnane, MD, PhD

Profile

I am a research-focused, board-certified Anatomic and Clinical pathologist at Vanderbilt University with specialized training in the molecular pathology of breast cancer.

I began my research career as a post-baccalaureate cancer research fellow in the laboratory of Louis Staudt at the National Cancer Institute. This work in diffuse large B cell lymphoma, published in Nature in 2000 and validated in the New England Journal of Medicine in 2002, was the first to segregate clinically and molecularly distinct subtypes of diffuse large B-cell lymphoma based on gene expression. During my doctoral training, I developed multiplexed fluorescent assays to characterize the proteomic profile of the ERBB and PI3-kinase signaling pathways in large breast carcinoma cohorts and correlated the results to patient diagnosis, prognosis and response to targeted therapies, in the laboratory of David L. Rimm at Yale University.

I am continuing my career at Vanderbilt with a focus on biomarker discovery and validation for the prediction of treatment resistance and recurrence in breast cancer in the Carlos Arteaga laboratory. I have utilized the accrued tissue in the BRE0776 presurgical letrozole trial in order to study of mechanisms of resistance to endocrine therapy. Through multi-platform molecular profiling, I hope to identify actionable somatic alterations and uncover additional therapeutic liabilities for improved diagnosis and treatment of early breast cancer. A long-term goal is to develop a cost-effective, protein-based biomarker assay to predict treatment response in ER+ breast cancer, informed by my experience with quantitative protein measurements in tissue.

I am also involved in several other projects at the Vanderbilt-Ingram Cancer Center, including the evaluation of clonal selection in breast cancer triplets of pre-treatment biopsy, post-treatment, and metastatic tissue samples and the development of biomarker assays for sensitive situ detection of novel molecular alterations in genes such as ESR1, FGFR1, JAK2, and MCL-1, discovered through multi-omic profiling.

Publications

The following timeline graph is generated from all co-authored publications.

1. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL (2015) Cancer Res 75(2): 405-14
   › Primary publication · 25480943 (PubMed) · PMC4297507 (PubMed Central)
2. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Owens P, Pickup MW, Novitskiy SV, Giltnane JM, Gorska AE, Hopkins CR, Hong CC, Moses HL (2015) Oncogene 34(19): 2437-49
   › Primary publication · 24998846 (PubMed) · PMC4689138 (PubMed Central)
3. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Ondrejka SL, Jegalian AG, Kim AS, Chabot-Richards DS, Giltnane J, Czuchlewski DR, Shetty S, Sekeres MA, Yenamandra A, Head D, Jagasia M, Hsi ED (2014) Haematologica 99(9): e148-51
   › Primary publication · 24951465 (PubMed) · PMC4562545 (PubMed Central)
4. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Giltnane JM, Balko JM (2014) Discov Med 17(95): 275-83
   › Primary publication · 24882719 (PubMed)
5. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
   › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)
6. Quantitative, fluorescence-based in-situ assessment of protein expression. Moeder CB, Giltnane JM, Moulis SP, Rimm DL (2009) Methods Mol Biol : 163-75
   › Primary publication · 19381954 (PubMed)
7. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Giltnane JM, Moeder CB, Camp RL, Rimm DL (2009) Cancer 115(11): 2400-9
   › Primary publication · 19330842 (PubMed) · PMC2756449 (PubMed Central)
8. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL (2008) Arch Pathol Lab Med 132(10): 1635-47
   › Primary publication · 18834223 (PubMed)
9. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL (2007) J Clin Oncol 25(21): 3007-14
   › Primary publication · 17634479 (PubMed)
10. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) Cancer Cell 3(2): 185-97
    › Primary publication · 12620412 (PubMed)

View full member profile

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword